On this page you will find useful information regarding which patients should be initiated on UPTRAVI®, guidance on prescribing and administering UPTRAVI®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Access the UPTRAVI® SmPC and patient information leaflet.
Guidance on correctly starting your patient on their UPTRAVI® journey.
The My UPTRAVI® Treatment Guide explains the dosing process and supports patients along their UPTRAVI® journey.
Learn how PAH can impact patients with scleroderma.
Learn about the investigation and referral pathways for patients with scleroderma and suspected PAH.
Learn how PAH can impact patients with CHD.
Learn about the investigation and referral pathways of patients with CHD and suspected PAH.
Discover how UPTRAVI® can provide long-term benefits for patients with PAH.
UPTRAVI® has a well-characterised and generally manageable safety profile.
Adding UPTRAVI® is recommended at the first sign of intermediate risk.